In the latest cover story, "2025 Trends", in Biospectrum Asia Edition, Zhao Lijian, CEO of BGI Genomics, was invited to discuss three key trends in healthcare for 2025 that focus on digitalsation in proactive health management and the transformative role of advanced technology in disease diagnosis and prevention.

AI’s Future Integration into Clinical Practice: In the coming years, AI will become seamlessly integrated into healthcare, transforming both disease detection and patient care. Advanced neural network models trained on multi-omics data will enhance our ability to predict diseases with unprecedented accuracy, making diagnostics faster and more reliable. The rise of human-machine interactions through telehealth will revolutionise medical consultations. Imagine a future where Large Language Models, like ChatGPT, provide instant, accurate medical advice, easing the burden on healthcare professionals and drastically reducing patient wait times from weeks to mere moments.

AI-Integrated Multi-omics-Based Disease Risk Prediction Models: AI-powered models are increasingly being used for the early prediction and prevention of major diseases, such as malignant tumours and severe cardiovascular conditions. By integrating multi-omics data, spanning across genomics, proteomics, transcriptomics, epigenomics, metabolomics, and microbiomes, these models recreate digital representations of biological processes. This digitalisation allows for the simulation of disease progression and the effects of various interventions, using machine learning to tailor personalised treatment solutions. This approach gives clinicians critical insights for selecting the most effective treatment strategies while minimising unnecessary side effects and reducing patient suffering.

Proactive Health Monitoring Model: The future of healthcare is moving beyond treatment and diagnostics to proactive health management. Our vision involves creating a comprehensive health model for continuous individual monitoring, integrating imaging data, multi-omics diagnostics, and lifestyle information to establish a 'life index'. BGI Genomics has developed such a proactive health system model, which represents a groundbreaking approach to disease prevention and personalised health management. This holistic index provides a detailed view of an individual’s health risks and outcomes, empowering proactive and informed health management.

First Published: BioSpectrum Asia Edition December 2024

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.

Read more

China Daily | Zhao Lijian: The Health Silk Road Breaks Barriers for Better Well-Being

Advancing Healthcare in Uzbekistan: BGI Genomics CEO's Vision Shared on Uzbekistan's National Television